File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1177/1534735410378743
- Scopus: eid_2-s2.0-79953704228
- PMID: 20702488
- WOS: WOS:000289157000006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Regulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a Chinese medicinal formula, in vitro and in vivo
Title | Regulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a Chinese medicinal formula, in vitro and in vivo | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Authors | |||||||||||
Keywords | Chinese medicine decoction colon cancer metastasis and multidrug resistance proliferation Tian-Xian liquid | ||||||||||
Issue Date | 2011 | ||||||||||
Publisher | Sage Publications, Inc.. The Journal's web site is located at http://www.sagepub.com/journalsProdDesc.nav?prodId=Journal201510 | ||||||||||
Citation | Integrative Cancer Therapies, 2011, v. 10 n. 1, p. 58-69 How to Cite? | ||||||||||
Abstract | Ethnopharmacological relevance. Tian-Xian liquid (TXL), a commercially available Chinese medicine decoction, has been used as an anticancer dietary agent for more than 10 years without reported side effects. Aim of the study. The safety and quality consistency of TXL and its mechanisms of action on antiproliferation, antimetastasis, and reversion of multidrug resistance (MDR) regimens were explored. Materials and methods. In this study, an atomic absorption spectrophotometer and reversed phase high performance liquid chromatography with photodiode array detection (HPLC-DAD) were used to evaluate the main toxic elements and the quality consistency among different batches of TXL extracts, respectively. HT29 human colon cancer cell line and tumor-bearing nude mice were used. TXL was provided by China-Japan Feida Union Company Limited. The effect of TXL on in vitro proliferation of HT29 human colon cancer cell line was examined. The percentages of treated cells distributed in different phases of the cell cycles were analyzed by flow cytometry. Antiproliferative effect after treatment with TXL was assessed by determination of the protein levels of p21, cyclinD1, PCNA, and cdk-2, which are the key regulators for cell cycle progression. Meanwhile, the protein levels of MMP-1 and MDR-1 (multidrug resistance protein-1) were also determined to assess the effect of TXL on antimetastasis and reversion of MDR regimen, respectively. Results. The contents of main toxic elements were lower in TXL extract compared with the standard set by the Department of Health of the Government of Hong Kong Special Administrative Region (SAR). Our HPLC results showed that the relative standard deviations of the amount of the 5 standards were less than 5% in different batches of TXL. Immunoblotting analysis revealed a dramatic induction of cyclin kinase inhibitor p21 as well as an inhibition of cyclinD1, PCNA, and cdk-2 in the TXL-treated in vitro models, thereby, impeding cell progression from G1/S phase. Results obtained from the in vivo study also demonstrated that TXL upregulated the protein level of p21 and downregulated the protein levels of MMP-1 and MDR-1. Conclusions. Results obtained from the present investigation not only demonstrate the safety and quality of TXL extract but also demonstrate that TXL possesses antiproliferative and antimetastatic activities and brings about reversion of MDR on HT29 cell and on xenografted tissue in tumor-implanted nude mice. © The Author(s) 2011. | ||||||||||
Persistent Identifier | http://hdl.handle.net/10722/127608 | ||||||||||
ISSN | 2023 Impact Factor: 2.9 2023 SCImago Journal Rankings: 0.687 | ||||||||||
ISI Accession Number ID |
Funding Information: This research was supported in part by a grant from Seed Funding Programme for Applied Research (no. 200807160015), Small Project Funding (no. 200807176239), the University of Hong Kong, and the contract research funding from China-Japan Feida Union Company Limited. | ||||||||||
References | |||||||||||
Grants |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sze, SCW | en_HK |
dc.contributor.author | Wong, KL | en_HK |
dc.contributor.author | Liu, WK | en_HK |
dc.contributor.author | Ng, TB | en_HK |
dc.contributor.author | Wong, JH | en_HK |
dc.contributor.author | Cheung, HP | en_HK |
dc.contributor.author | Yow, CML | en_HK |
dc.contributor.author | Chu, ESM | en_HK |
dc.contributor.author | Liu, Q | en_HK |
dc.contributor.author | Hu, YM | en_HK |
dc.contributor.author | Tsang, KW | en_HK |
dc.contributor.author | Lee, WS | en_HK |
dc.contributor.author | Tong, Y | en_HK |
dc.date.accessioned | 2010-10-31T13:35:23Z | - |
dc.date.available | 2010-10-31T13:35:23Z | - |
dc.date.issued | 2011 | en_HK |
dc.identifier.citation | Integrative Cancer Therapies, 2011, v. 10 n. 1, p. 58-69 | en_HK |
dc.identifier.issn | 1534-7354 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/127608 | - |
dc.description.abstract | Ethnopharmacological relevance. Tian-Xian liquid (TXL), a commercially available Chinese medicine decoction, has been used as an anticancer dietary agent for more than 10 years without reported side effects. Aim of the study. The safety and quality consistency of TXL and its mechanisms of action on antiproliferation, antimetastasis, and reversion of multidrug resistance (MDR) regimens were explored. Materials and methods. In this study, an atomic absorption spectrophotometer and reversed phase high performance liquid chromatography with photodiode array detection (HPLC-DAD) were used to evaluate the main toxic elements and the quality consistency among different batches of TXL extracts, respectively. HT29 human colon cancer cell line and tumor-bearing nude mice were used. TXL was provided by China-Japan Feida Union Company Limited. The effect of TXL on in vitro proliferation of HT29 human colon cancer cell line was examined. The percentages of treated cells distributed in different phases of the cell cycles were analyzed by flow cytometry. Antiproliferative effect after treatment with TXL was assessed by determination of the protein levels of p21, cyclinD1, PCNA, and cdk-2, which are the key regulators for cell cycle progression. Meanwhile, the protein levels of MMP-1 and MDR-1 (multidrug resistance protein-1) were also determined to assess the effect of TXL on antimetastasis and reversion of MDR regimen, respectively. Results. The contents of main toxic elements were lower in TXL extract compared with the standard set by the Department of Health of the Government of Hong Kong Special Administrative Region (SAR). Our HPLC results showed that the relative standard deviations of the amount of the 5 standards were less than 5% in different batches of TXL. Immunoblotting analysis revealed a dramatic induction of cyclin kinase inhibitor p21 as well as an inhibition of cyclinD1, PCNA, and cdk-2 in the TXL-treated in vitro models, thereby, impeding cell progression from G1/S phase. Results obtained from the in vivo study also demonstrated that TXL upregulated the protein level of p21 and downregulated the protein levels of MMP-1 and MDR-1. Conclusions. Results obtained from the present investigation not only demonstrate the safety and quality of TXL extract but also demonstrate that TXL possesses antiproliferative and antimetastatic activities and brings about reversion of MDR on HT29 cell and on xenografted tissue in tumor-implanted nude mice. © The Author(s) 2011. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Sage Publications, Inc.. The Journal's web site is located at http://www.sagepub.com/journalsProdDesc.nav?prodId=Journal201510 | en_HK |
dc.relation.ispartof | Integrative Cancer Therapies | en_HK |
dc.rights | Integrative Cancer Therapies. Copyright © Sage Publications, Inc.. | - |
dc.subject | Chinese medicine decoction | en_HK |
dc.subject | colon cancer | en_HK |
dc.subject | metastasis and multidrug resistance | en_HK |
dc.subject | proliferation | en_HK |
dc.subject | Tian-Xian liquid | en_HK |
dc.subject.mesh | Colonic Neoplasms - drug therapy - genetics - metabolism - pathology | - |
dc.subject.mesh | Cyclin-Dependent Kinase Inhibitor p21 - biosynthesis - genetics | - |
dc.subject.mesh | Drugs, Chinese Herbal - adverse effects - chemistry - pharmacology | - |
dc.subject.mesh | Matrix Metalloproteinase 1 - biosynthesis - genetics | - |
dc.subject.mesh | P-Glycoprotein - biosynthesis - genetics | - |
dc.title | Regulation of p21, MMP-1, and MDR-1 expression in human colon carcinoma HT29 cells by Tian Xian liquid, a Chinese medicinal formula, in vitro and in vivo | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1534-7354&volume=&spage=DOI:10.1177/1534735410378743&epage=&date=2010&atitle=Regulation+of+p21,+MMP-1+and+MDR-1+expression+in+Human+colon+carcinoma+HT29+by+Tian+Xian+Liquid,+a+Chinese+Medicine+Formula,+in+vitro+and+in+vivo | en_HK |
dc.identifier.email | Sze, SCW: stephens@hku.hk | en_HK |
dc.identifier.email | Tong, Y: tongyao@hku.hk | en_HK |
dc.identifier.authority | Sze, SCW=rp00514 | en_HK |
dc.identifier.authority | Tong, Y=rp00509 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1177/1534735410378743 | en_HK |
dc.identifier.pmid | 20702488 | - |
dc.identifier.scopus | eid_2-s2.0-79953704228 | en_HK |
dc.identifier.hkuros | 197172 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-79953704228&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 10 | en_HK |
dc.identifier.issue | 1 | en_HK |
dc.identifier.spage | 58 | en_HK |
dc.identifier.epage | 69 | en_HK |
dc.identifier.eissn | 1552-695X | - |
dc.identifier.isi | WOS:000289157000006 | - |
dc.publisher.place | United States | en_HK |
dc.relation.project | Mechanical Study of Tian Xian Liquid (TXL), Chinese Medicine Formula, in Treatment of Colon Cancer in vitro | - |
dc.relation.project | Bioactive components of Tian Xian Liquid as a potential drug candidate for the treatment of colon cancer | - |
dc.identifier.scopusauthorid | Sze, SCW=23482617000 | en_HK |
dc.identifier.scopusauthorid | Wong, KL=47861480700 | en_HK |
dc.identifier.scopusauthorid | Liu, WK=37045953300 | en_HK |
dc.identifier.scopusauthorid | Ng, TB=35311803300 | en_HK |
dc.identifier.scopusauthorid | Wong, JH=34874358200 | en_HK |
dc.identifier.scopusauthorid | Cheung, HP=37033470100 | en_HK |
dc.identifier.scopusauthorid | Yow, CML=47861516500 | en_HK |
dc.identifier.scopusauthorid | Chu, ESM=13807807000 | en_HK |
dc.identifier.scopusauthorid | Liu, Q=36063708000 | en_HK |
dc.identifier.scopusauthorid | Hu, YM=7407116890 | en_HK |
dc.identifier.scopusauthorid | Tsang, KW=47861536800 | en_HK |
dc.identifier.scopusauthorid | Lee, WS=12788473400 | en_HK |
dc.identifier.scopusauthorid | Tong, Y=9045384000 | en_HK |
dc.identifier.issnl | 1534-7354 | - |